|
|
|
|
| LEADER |
03364nam a2200433 a 4500 |
| 001 |
1900705 |
| 005 |
20171111234734.0 |
| 008 |
050909s2004 dcua ob 000 0 eng c |
| 020 |
|
|
|a 0309526191
|q (PDF)
|
| 020 |
|
|
|a 9780309526197
|q (PDF)
|z 0309089794
|q (pbk.)
|q (pbk.)
|
| 040 |
|
|
|a BUF
|b eng
|e pn
|z 9780309089791
|
| 050 |
|
4 |
|a RA638
|
| 240 |
1 |
0 |
|a Financing vaccines in the twenty-first century
|
| 245 |
0 |
0 |
|a Financing vaccines in the 21st century :
|b assuring access and availability /
|c Committee on the Evaluation of Vaccine Purchase Financing in the United States, Board on Health Care Services, Institute of Medicine.
|
| 246 |
3 |
|
|a Financing vaccines in the twenty-first century
|
| 260 |
|
|
|a Washington, D.C. :
|b National Academies Press,
|c ©2004.
|
| 300 |
|
|
|a 1 online resource (xiii, 247 pages) :
|b illustrations
|
| 504 |
|
|
|a Includes bibliographical references (pages 211-220).
|
| 505 |
0 |
|
|a Introduction -- Background -- Conceptual framework for the study -- Study process -- Summing up -- Organization of the report -- Origins and rationale of immunization policy -- Legislative history of vaccine policy -- Shared federal and state responsibility for financing -- Shared public and private responsibility for coverage -- Public and private delivery systems -- Private vaccine production -- The setting national of vaccine policy -- Findings -- Public and private insurance coverage -- Public insurance coverage -- Private insurance coverage -- Barriers to a well-functioning immunization finance system -- Findings -- The delivery system -- Delivery of adult and childhood vaccines -- The work of immunizing -- Provider reimbursement -- Barriers to a well-functioning immunization delivery system -- Findings -- Vaccine supply -- Size and growth of the vaccine market -- Vaccine production -- Cost structure -- Research and development -- Industry concentration -- Regulation -- Pricing -- Shortages -- Stockpiles -- CDC contracting -- Barriers to a well-functioning vaccine supply system -- Findings -- Conclusions and alternative strategies -- Conclusions -- Alternative strategies -- Weighing the alternatives -- Recommendations -- Final observations.
|
| 650 |
|
0 |
|a Vaccination
|x Planning.
|z United States
|
| 650 |
|
0 |
|a Vaccines
|x Economic aspects
|z United States.
|
| 650 |
|
0 |
|a Vaccination
|x Economic aspects
|z United States.
|
| 650 |
|
0 |
|a Vaccination
|x Government policy
|z United States.
|
| 650 |
|
2 |
|a Mass Vaccination
|x economics.
|
| 650 |
|
2 |
|a Vaccines
|x economics.
|
| 650 |
|
4 |
|a Vaccination
|x Economic aspects
|z United States.
|
| 650 |
|
4 |
|a Vaccination
|x Government policy
|z United States.
|
| 650 |
|
4 |
|a Vaccination
|x Planning.
|z United States
|
| 650 |
|
4 |
|a Vaccines
|x Economic aspects
|z United States.
|
| 650 |
|
6 |
|a Vaccination
|x Planification.
|z États-Unis
|
| 650 |
|
6 |
|a Vaccins
|x Aspect économique
|z États-Unis.
|
| 650 |
|
6 |
|a Vaccination
|x Aspect économique
|z États-Unis.
|
| 650 |
|
6 |
|a Vaccination
|x Politique gouvernementale
|z États-Unis.
|
| 650 |
|
7 |
|a MEDICAL
|x Health Risk Assessment.
|
| 650 |
|
7 |
|a MEDICAL
|x Epidemiology.
|
| 651 |
|
2 |
|a United States.
|
| 710 |
2 |
|
|a Institute of Medicine (U.S.).
|b Committee on the Evaluation of Vaccine Purchase Financing in the United States.
|
| 856 |
4 |
0 |
|u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=104500
|
| 952 |
|
|
|a CY-NiOUC
|b 5a0465be6c5ad14ac1eed9fa
|c 998a
|d 945l
|e -
|t 1
|x m
|z Books
|
